NEW YORK (AP) — Shares of respiratory drug maker KaloBios Pharmaceuticals are inching higher on the first day of trading.
KaloBios Pharmaceuticals Inc. says its initial public offering of 8.8 million shares priced at $8 per share. The company's stock is now trading on the Nasdaq Global Market under the ticker symbol "KBIO." In early trading the stock gain 9 cents to $8.09.
The underwriters of the offering will have the option to buy another 1.3 million shares to cover any over allotments.
In January KaloBios said it intended to sell 3.9 million shares for $12 to $14 per share.
The company is based in South San Francisco, Calif., and it is studying antibacterial drugs and treatments for cystic fibrosis and blood cancers.
Planned Parenthood hires forensic analysis firm to debunk 'heavily edited' undercover videos
Small But Honest Columnist Again Forced to Correct Highest-Rated Show on Cable TV | Human Events
Panicky Democratic donors wonder: Are we really going to bet the White House on this shady loser? - Hot Air
Vox "Smart Take" Pushes Gun Confiscation. Here's What Would Happen If They Tried. - Bearing Arms - 2nd Amendment, Gun Confiscation
RIP, the Jeb Bush 2016 Campaign | RedState
Katie Pavlich - Hillary: My Republican Opponents Treat Women Just Like Terrorists Do
Night Watch - Japan Might Finally Be Ready to Join the War on Terror